- Home
- BLX vs AGIO Comparison
BLX vs AGIO Comparison
Compare BLX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLX | AGIO |
|---|---|---|
| Founded | 1977 | 2007 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BLX | AGIO |
|---|---|---|
| Price | $50.54 | $31.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $69.65 | $46.11 |
| AVG Volume (30 Days) | 162.3K | ★ 1.2M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $10.52 | $227.92 |
| Revenue Next Year | $10.12 | $96.10 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.29 | $22.24 |
| 52 Week High | $63.20 | $46.00 |
Technical Indicators
Market Signals| Indicator | BLX | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 45.76 |
| Support Level | $48.56 | $31.25 |
| Resistance Level | $51.60 | $35.77 |
| Average True Range (ATR) | 1.48 | 1.86 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 29.32 | 34.43 |
Price Performance
Historical ComparisonAbout BLX Banco Latinoamericano de Comercio Exterior S.A.
Bladex Inc is a Panama-based bank focused on providing financial solutions to financial institutions and corporations throughout Panama.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.